T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-γ mechanisms that cannot be predicted from in vitro T cell characteristics

Journal of Immunology

Volumn 165, Issue 12, 2000, Pages 7116-7124

  Peng, L ^a   Krauss, J C ^a   Plautz, G E ^a   Mukai, S ^a   Shu, S ^a   Cohen, P A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; CYTOKINE; FAS LIGAND; GAMMA INTERFERON; PERFORIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; FEMALE; IN VITRO STUDY; KNOCKOUT MOUSE; LUNG METASTASIS; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNOLOGY; TUMOR REJECTION;

EID: 0034672005     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.12.7116     Document Type: Article

References (47)

1. Spontaneous regression of malignant melanoma pathologic and immunologic study in a ten year survivor
2. In vivo elimination by specific effector cells of an established syngeneic rat Moloney virus-induced sarcoma
3. + T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection
4. + T cells in the tumor and blood is associated with efficient local IL-12 gene therapy of cancer
5. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
6. Tumor immumty in perforin-deficient mice a role for CD95 (Fas/APO-1)
7. The CTL's kiss of death
8. Lymphocyte-mediated cytotoxicity two pathways and multiple effector molecules
9. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice
10. A central role of perforin in cytolysis?
11. The Fas death factor
12. The Fas-based mechanism of lymphocytotoxicity
13. Decreased tumor surveillance in perforin-deficient mice
14. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L)
15. Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes
16. + tumor-infiltrating lymphocytes
17. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2
18. Local T helper cell signals by lymphocytes infiltrating intraocular tumors
19. B7 costimulation is necessary for the activation of the lytic function in cytotoxic T lymphocyte precursors
20. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice
21. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity
22. + T cells against the wild-type tumor correlation with antigen presentation capability
23. + T cells efficacy is limited by migration away from the site and induction of nonresponsiveness
24. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines
25. 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy
26. T-cell-receptor engagement and tumor ICAM-1 up-regulation are required to by-pass low susceptibility of melanoma cells to autologous CTL-mediated lysis
27. Treatment of subcutaneous tumor with adoptively transferred T cells
28. Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes
29. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes
30. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells
31. +/CD62L low T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression
32. Cross presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors
33. Critical role of CD11a (LFA-1) in therapeutic efficacy of systemically transferred antitumor effector T cells
34. Differences in the effects of host suppression on the adoptive immunotherapy of subcutaneous and visceral tumors
35. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells
36. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes
37. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells
38. Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intracranial tumors
39. + T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen
40. Requirements for T cell recognition and elimination of retrovirally-transformed cells
41. Propagation of murine and human T cells with defined antigen specificity and function
42. + T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells
43. The impact of interferon γ receptor expression on the mechanism of escape from host immune surveillance in hepatocellular carcinoma
44. Defective presentation of endogenous antigens by a murine sarcoma implications for the failure of an anti-tumor immune response
45. + T cells in culture with maintained antigen specificity
46. IL-2 signaling in human monocytes revolves the phosphorylation and activation of p59(hck) 1
47. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production